RE: 2022 CAPA Election

December 19, 2021

Dear CAPA Members:

Thank you very much for your nomination. The CAPA Election Committee is pleased to announce four (4) qualified candidates to fill three (3) positions on the Board of Directors (BOD) for years 2022-2024. The candidates are listed below in the order of receipt of their nominations.

The election will be held from Friday January 7, 2021 at 12:00 pm (noontime) EST to Sunday January 9, 2021 at 12:00 pm (noontime) EST.

Thank you in advance for your participation in the 2022 CAPA election.

CAPA Election Committee

Final list of candidates for BOD (in the order of nomination receipt):

Deyin Xing, MD., Ph.D. (邢德印) Johns Hopkins University School of Medicine

Hui Zhu, MD., Ph.D. (朱慧) HCA North Cypress Medical Center at Houston

Jinping Lai, MD, Ph.D. (赖金平) Kaiser Permanent in Northern California

Gang Wang, MD, Ph.D., FRCPC (王罡) University of British Columbia




Deyin Xing, MD, PhD 邢德印

Associate Professor of Pathology, Associate Professor of Oncology, Associate Professor of Gynecology and Obstetrics, Associate Director of Gynecologic Pathology In-house Service Department of Pathology, The Johns Hopkins University School of Medicine

Dr. Deyin Xing earned his medical degree in 1999 from Nankai University in Tianjin, China and completed a doctoral degree in oncology at Peking Union Medical College in Beijing. After postdoctoral/research training at Massachusetts General Hospital/Harvard Medical School and then at Massachusetts Institute of Technology, Dr. Xing resumed his clinical career as an anatomic pathology resident in 2011 in the department of pathology at the University of Alabama at Birmingham. In 2014, he came to Hopkins for a gynecologic pathology fellowship training mentored by Dr. Robert Kurman, Dr. Biggy Ronnett and Dr. Russell Vang. Dr. Xing joined the faculty of Hopkins in the Division of Gynecologic Pathology after he finished his training.

Dr. Xing is currently an Associate Professor of Pathology, Oncology, Gynecology and Obstetrics at the Johns Hopkins University School of Medicine and serves as Associate Director of Gynecologic Pathology In-house Service at the Johns Hopkins Hospital. He also helps administrating international telepathology service at Hopkins. He has published more than 70 scientific articles and several book chapters. He has served as a section or associate editor/editorial board for 9 scientific Journals and as invited reviewer for 39 scientific journals. He was invited to give pathology lectures in China, Canada, and Brazil. He is currently served in USCAP Abstract Review Board.

Dr. Xing is currently an active member of CAPA, and he joined CAPA in 2016. He has/had been serving on several CAPA committees including Award Committee and Online Education Committee. He has been coordinating Gynecologic Pathology online lectures since 2018. He is currently serving the chair of CAPA GYN subcommittee. Dr. Xing helped and organized gynecologic pathology session in 2021 CAPA Annual Diagnostic Courses. Dr. Xing feels CAPA is a unique community he strongly belongs to, and a unique society that unites all Chinese pathologists in this country and stands for our voice. He is eager to serve all CAPA members and devote his efforts to promote CAPA further nationally and internationally. Following other and former BOD Members' footsteps, Dr. Xing aims to better understand members' professional needs, provide opportunities for members' career development, and encourage communication and collaboration among members. For example, he is happy to help our peer pathologists' questions about gynecologic pathology at society level and/or personal level. Beyond that, he looks forward to the opportunity to better serve our own community from all aspects.



I (朱慧) am AP/CP and Cytopathology Board Certified. Currently I'm working as staff pathologist at HCA North Cypress Medical Center at Houston Texas.

I got my medical degree from Peking University Health Science Center and PhD degree in Biochemistry from Weill Cornell Medical College. After completing AP/CP Residency and Cytopathology Fellowship training at Cleveland Clinic Foundation, I worked at University at Buffalo for one year, then joined the University of Texas (UT) McGovern Medical School. I worked at UT for five years and was promoted as associate professor in 2021. I decided to change career path and joined HCA in December 2021.

During the past six years, I had progressed successfully as an academic pathologist. My clinical service responsibilities include Cytopathology and surgical pathology with focuses on Head and Neck Pathology (adjunct faculty in the Department of Otorhinolaryngology-Head and Neck Surgery from 2018-2021), Gynecological Pathology, and Bone and Soft Tissue Pathology. My teaching devotion had won me Dean's Excellence in Teaching four times (2018-2021) and Excellence in Teaching Anatomic Pathology three times (2019-2021) at UT. My administrative roles included Associate Director of Cytopathology at UT, Medical Director of Cytopathology Laboratory. I also enjoyed research and have published more than 40 articles in peer reviewed journals.

I have been a CAPA member since 2016 and participated in several services. I served as members in CAPA Cytopathology Subcommittee in 2018-2019; CAPA Head and Neck Pathology Subcommittee in 2019-2020; CAPA Research Committee in 2020-2021; and CAPA Award Committee from 2019-2021. I have also been actively giving lectures in CAPA Webinar lecture series in Head and Neck Pathology, Thyroid Cytopathology, and Salivary Gland Cytopathology. I am grateful for the support from CAPA in my career development. I am looking forward to the opportunity of serving CAPA as member of Board of Directors.



Dr. Jinping Lai (赖金平) received his MD and PhD degrees from XiangYa School of Medicine of the Central South University in China. Dr. Lai practiced as an ENT-Head and Neck surgeon and surgical oncologist at XiangYa Hospital for many years before he moved to the US. He then studied molecular pathogenesis of hepatocellular carcinoma at Mayo Clinic in Rochester (he was a research assistant professor at Mayo Clinic College of Medicine for 5 years) and went to NCI/NIH Clinical Center for pathology residency. After that, Dr. Lai had two fellowships in surgical pathology and GI/Liver pathology at Cedars-Sinai Medical Center in Los Angeles. He joined Kaiser Permanente in Northern California in 2019 after practicing academic pathology with interests in GI/liver, ENT head and neck pathology for several years as an assistant professor at St. Louis University Hospital and associate professor at the University of Florida in Gainesville's Shands Hospital, respectively. Dr. Lai was a NASH Clinical Research Network (CRN) pathologist. He has published more than 190 peer-reviewed journal articles in journals such as Gastroenterology, Hepatology, Journal of Hepatology, Diabetic Care, Oncogene, Modern Pathology, AJSP, Head and Neck Pathology, etc., a book of Practical Interpretation of Liver Biopsy, and many book chapters including the book of WHO Classification of Tumors of the Digestive System (5th Edition, 2019). He serves as associate editor and editorial board member for many medical journals such as Frontiers in Endocrinology, Frontiers in Oncology, Cancers, Journal of Clinical and Translational Pathology (CAPA), etc. Currently, Dr. Lai is serving as the GI/liver and ENT Head-Neck pathology clinical research lead and GI/liver and ENT Head-Neck pathology consultant in Kaiser Permanente Northern California. He is also adjunct associate professor at the University of Florida College of Medicine in Gainesville.

Dr. Lai is a lifetime CAPA member and gave talks at CAPA diagnostic courses in 2020 and 2021. He is currently serving as the chair of CAPA private practice committee, a CAPA EC member and a member of CAPA ENT-Head and Neck Pathology committee. He would like to apply to a CAPA BOD member for the next term and continue to serve all CAPA members.



Gang Wang (王罡), MD PhD FRCPC Clinical Assistant Professor, Director of BC Cancer GU Tumor Bank, Director of Histology and Immunohistochemistry, Department of Pathology and Lab Medicine, BC Cancer Vancouver Centre, University of British Columbia.

Dr. Wang received his MD degree from Tongji Medical University (Wuhan, China) and his Ph.D. in Pathology from the University of British Columbia (Vancouver, Canada). After completing his Anatomic Pathology residency at the University of British Columbia, he served as a Genitourinary Pathology fellow at the MD Anderson Cancer Center in Houston. After fellowship training, He joined the University of British Columbia faculty as a Clinical Assistant Professor and has worked as a consultant pathologist in BC Cancer Vancouver Center since 2017. Dr. Wang is currently the director of BC Cancer GU Tumor Bank and the director of Histology and Immunohistochemistry.

Dr. Wang has a long-term research interest in genitourinary tumors, and his translational research is supported by Bladder Cancer Canada, University of British Columbia, and industry collaborative grants. He is the chapter author of "Urinary Bladder Pathology" and "Practical Cytopathology Frequently Asked Questions". Dr. Wang authored more than 50 peer-reviewed original articles. He was an invited speaker for the CAPA diagnostic course and online lecture series, The Canadian Anatomic & Molecular Pathology Online Course. He is also the reviewer for more than 15 academic journals. He has been awarded the "New Faculty Research Award" from UBC Faculty of Medicine and the "Excellent in Research and Discovery Award" from UBC Department of Pathology. As an academic pathologist, Dr. Wang has trained more than 30 residents and fellows and served as mentors for many of them.

Dr. Wang has served Medical Staff Engagement Society (MSES) of the Provincial Health Services Authority (PHSA) and Priority and Evaluation Committee (PEC) of BC Cancer and is also an active member of the Chinese Canadian Medical Society (CCMS). He is a firm believer of CAPA and has been a lifetime member since 2016. Dr. Wang has a strong willingness to dedicate himself to CAPA and make it a mainstream professional organization representing and promoting the success of every Chinese pathologist in academic centers or private practice.